RespireRx Pharmaceuticals Inc (RSPI) - Strategic SWOT Analysis Review

August 2019 | 27 pages | ID: R443163259EEN
GlobalData

Abstracts

RespireRx Pharmaceuticals Inc (RSPI) - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services.

This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.

Scope

• Business description – A detailed description of the company’s operations and business divisions.
• Corporate strategy – GlobalData’s summarization of the company’s business strategy.
• SWOT analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
• Company history – Progression of key events associated with the company.
• Major products and services – A list of major products, services and brands of the company.
• Key competitors – A list of key competitors to the company.
• Key employees – A list of the key executives of the company.
• Executive biographies – A brief summary of the executives’ employment history.
• Key operational heads – A list of personnel heading key departments/functions.
• Important locations and subsidiaries – A list of key locations and subsidiaries of the company, including contact details.

Highlights

RespireRx Pharmaceuticals Inc (RespireRx), formerly Cortex Pharmaceuticals, Inc. involved in the discovery, development and commercialization of innovative products for the treatment of various respiratory disorders (RD) and CNS problems. RespireRx focuses on attention deficit hyperactivity disorder, obstructive sleep apnea (OSA), spinal cord injury and other neurological disorders. Its lead product, Dronabinol, an oral capsule drug product completed Phase II trials for the treatment of OSA. The company’s other pipeline products include CX1739 in Chronic CSA, CX717 in spinal cord injury and opioid; CX1942 in drug induced RD. RespireRx is headquartered in Glen Rock, New Jersey, the US.

RespireRx Pharmaceuticals Inc Key Recent Developments

Jan 03,2019: RespireRx Pharmaceuticals names James Sapirstein as executive vice board chairman
Dec 10,2018: Respirerx Pharmaceuticals executives presenting at the international cannabinoid derived pharmaceuticals summit
Jul 25,2018: RespireRx Pharmaceuticals Announces Publication of Ampakine Data

Reasons to Buy

• Gain key insights into the company for academic or business research purposes. Key elements such as SWOT analysis and corporate strategy are incorporated in the profile to assist your academic or business research needs.
• Identify potential customers and suppliers with this report’s analysis of the company’s business structure, operations, major products and services and business strategy.
• Understand and respond to your competitors’ business structure and strategies with GlobalData’s detailed SWOT analysis. In this, the company’s core strengths, weaknesses, opportunities and threats are analyzed, providing you with an up to date objective view of the company.
• Examine potential investment and acquisition targets with this report’s detailed insight into the company’s strategic, business and operational performance.

Note: Some sections may be missing if data is unavailable for the company.

Contents

SECTION 1 - ABOUT THE COMPANY

RespireRx Pharmaceuticals Inc - Key Facts
RespireRx Pharmaceuticals Inc - Key Employees
RespireRx Pharmaceuticals Inc - Key Employee Biographies
RespireRx Pharmaceuticals Inc - Major Products and Services
RespireRx Pharmaceuticals Inc - History
RespireRx Pharmaceuticals Inc - Company Statement
RespireRx Pharmaceuticals Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Company Overview
RespireRx Pharmaceuticals Inc - Business Description
RespireRx Pharmaceuticals Inc - SWOT Analysis
SWOT Analysis - Overview
RespireRx Pharmaceuticals Inc - Strengths
RespireRx Pharmaceuticals Inc - Weaknesses
RespireRx Pharmaceuticals Inc - Opportunities
RespireRx Pharmaceuticals Inc - Threats
RespireRx Pharmaceuticals Inc - Key Competitors

SECTION 3 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

RespireRx Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
RespireRx Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
RespireRx Pharmaceuticals Inc, Recent Deals Summary

SECTION 4 – COMPANY’S RECENT DEVELOPMENTS

Jan 03, 2019: RespireRx Pharmaceuticals names James Sapirstein as executive vice board chairman
Dec 10, 2018: Respirerx Pharmaceuticals executives presenting at the international cannabinoid derived pharmaceuticals summit
Jul 25, 2018: RespireRx Pharmaceuticals Announces Publication of Ampakine Data

SECTION 5 – APPENDIX

Methodology
About GlobalData
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

RespireRx Pharmaceuticals Inc, Key Facts
RespireRx Pharmaceuticals Inc, Key Employees
RespireRx Pharmaceuticals Inc, Key Employee Biographies
RespireRx Pharmaceuticals Inc, Major Products and Services
RespireRx Pharmaceuticals Inc, History
RespireRx Pharmaceuticals Inc, Subsidiaries
RespireRx Pharmaceuticals Inc, Key Competitors
RespireRx Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
RespireRx Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
RespireRx Pharmaceuticals Inc, Recent Deals Summary

List Of Figures

LIST OF FIGURES

RespireRx Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
RespireRx Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2013 to YTD 2019

COMPANIES MENTIONED

Vivus Inc
Mylan Pharmaceuticals Inc
Collegium Pharmaceutical Inc
Celgene Corp
Abraxis BioScience Inc